Calliditas Therapeutics AB (CALT)
|Net Income (ttm)||-3.50M|
|Trading Day||January 15|
|Day's Range||30.10 - 30.56|
|52-Week Range||19.17 - 36.65|
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed i...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...
STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas w...
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the eff...
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 ...
STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as o...
Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.
STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.
Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephro... [Read more...]
Drug Manufacturers-Specialty & Generic
|IPO Date |
Jun 5, 2020
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for CALT is 48.00, which is an increase of 59.47% from the latest price.